Dynavax Technologies Corporation (0IDA.L)
USD 12.91
(-0.26%)
USD 12.91
(-0.26%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 252.41 Million USD | -0.77% |
| 2022 | 254.37 Million USD | -0.17% |
| 2021 | 254.8 Million USD | 18.74% |
| 2020 | 214.6 Million USD | -0.85% |
| 2019 | 216.44 Million USD | 114.58% |
| 2018 | 100.87 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 9.55 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | -100.0% |
| 2010 | 11.78 Million USD | 26.12% |
| 2009 | 9.34 Million USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 222.98 Million USD | 0.13% |
| 2024 Q2 | 223.27 Million USD | 0.13% |
| 2023 Q3 | 253.09 Million USD | -0.23% |
| 2023 Q2 | 253.67 Million USD | -0.12% |
| 2023 Q1 | 253.98 Million USD | -0.15% |
| 2023 Q4 | 252.41 Million USD | -0.27% |
| 2023 FY | 252.41 Million USD | -0.77% |
| 2022 Q4 | 254.37 Million USD | -0.02% |
| 2022 FY | 254.37 Million USD | -0.17% |
| 2022 Q2 | 254.7 Million USD | -0.12% |
| 2022 Q3 | 254.43 Million USD | -0.11% |
| 2022 Q1 | 255.01 Million USD | 0.08% |
| 2021 Q4 | 254.8 Million USD | -0.14% |
| 2021 FY | 254.8 Million USD | 18.74% |
| 2021 Q2 | 252.85 Million USD | 18.33% |
| 2021 Q1 | 213.68 Million USD | -0.43% |
| 2021 Q3 | 255.15 Million USD | 0.91% |
| 2020 FY | 214.6 Million USD | -0.85% |
| 2020 Q2 | 215.88 Million USD | -0.31% |
| 2020 Q3 | 215.25 Million USD | -0.29% |
| 2020 Q4 | 214.6 Million USD | -0.3% |
| 2020 Q1 | 216.55 Million USD | 0.05% |
| 2019 Q3 | 214.57 Million USD | 1.56% |
| 2019 Q2 | 211.27 Million USD | 0.25% |
| 2019 Q1 | 210.74 Million USD | 108.93% |
| 2019 FY | 216.44 Million USD | 114.58% |
| 2019 Q4 | 216.44 Million USD | 0.87% |
| 2018 FY | 100.87 Million USD | 0.0% |
| 2018 Q1 | 99.23 Million USD | 0.0% |
| 2018 Q2 | 99.77 Million USD | 0.54% |
| 2018 Q4 | 100.87 Million USD | 0.55% |
| 2018 Q3 | 100.31 Million USD | 0.55% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | -100.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q1 | 8.91 Million USD | -6.76% |
| 2015 Q2 | 7.96 Million USD | -10.68% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 9.55 Million USD | 0.0% |
| 2014 Q4 | 9.55 Million USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 FY | - USD | -100.0% |
| 2011 Q4 | - USD | -100.0% |
| 2011 Q2 | 12.73 Million USD | 11.63% |
| 2011 Q1 | 11.4 Million USD | -3.18% |
| 2011 Q3 | 12.34 Million USD | -3.08% |
| 2010 Q1 | 12.85 Million USD | 37.55% |
| 2010 Q4 | 11.78 Million USD | 2.59% |
| 2010 Q3 | 11.48 Million USD | -13.66% |
| 2010 Q2 | 13.3 Million USD | 3.51% |
| 2010 FY | 11.78 Million USD | 26.12% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | 9.34 Million USD | 0.0% |
| 2009 Q4 | 9.34 Million USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | -935.688% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -660.387% |
| Perrigo Company plc | 3.63 Billion USD | 93.052% |
| Illumina, Inc. | 1.48 Billion USD | 83.048% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.194% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -25141.8% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 96.862% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 98.052% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -45.274% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 90.661% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -972.34% |
| Waters Corporation | 2.3 Billion USD | 89.052% |
| Biogen Inc. | 7.18 Billion USD | 96.488% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -653.149% |
| Evolus, Inc. | 120.35 Million USD | -109.721% |
| Adicet Bio, Inc. | 17.7 Million USD | -1325.849% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -580.757% |
| bluebird bio, Inc. | 224.41 Million USD | -12.476% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 49.672% |
| FibroGen, Inc. | 89.69 Million USD | -181.412% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 90.771% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -7693.972% |
| Homology Medicines, Inc. | 43.17 Million USD | -484.626% |
| Geron Corporation | 35.05 Million USD | -620.145% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 89.227% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 34.92% |
| Myriad Genetics, Inc. | 130.9 Million USD | -92.833% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -26867.735% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -160.905% |
| Zoetis Inc. | 6.56 Billion USD | 96.155% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -5634.166% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 87.223% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 57.441% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 65.169% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -638.28% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 81.975% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -452.422% |
| Verastem, Inc. | 40.08 Million USD | -529.691% |
| Nektar Therapeutics | 112.62 Million USD | -124.123% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -41.752% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -8111.386% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 77.712% |
| OPKO Health, Inc. | 222.03 Million USD | -13.684% |
| Exelixis, Inc. | 189.94 Million USD | -32.891% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 2.277% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | -94.071% |
| Imunon, Inc. | 1.13 Million USD | -22055.67% |
| Blueprint Medicines Corporation | 610.96 Million USD | 58.685% |
| Insmed Incorporated | 1.19 Billion USD | 78.848% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 83.164% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -342.932% |
| TG Therapeutics, Inc. | 100.11 Million USD | -152.12% |
| Incyte Corporation | 29.16 Million USD | -765.572% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 43.467% |